Alkem Laboratories Ltd Share Price

Pharmaceuticals

NSE: ALKEM Mid Cap ISIN: INE540L01014

As on 18 April 2025 at 16:33 IST

₹ 4,953.30

-4.30

(-0.09%)

Sell Buy

Q3 Results:

Alkem Laboratories Q3 Results: Third quarter Total income fell 89.9% to ₹34.673 billion, from ₹341.75 billion in the same period last year. Net profit increased 6.0% to ₹6.408 billion on a yearly basis, compared to ₹6.043 billion in the same quarter last year.

About Alkem Laboratories Ltd

Alkem Laboratories Ltd was founded in 1973. It is a leading pharmaceutical company headquartered in Mumbai, Maharashtra. It specialises in developing, manufacturing, and marketing pharmaceutical formulations, generic drugs, APIs, and nutraceuticals. The company’s main products cover therapeutic areas such as anti-infective and pain and analgesics. It also covers areas like vitamins/minerals/nutrients, cardiac, diabetology, and gynaecology. They also provide products for neuro/central nervous system and dermatology. Alkem Laboratories holds the top position in the Indian trade generics market. This highlights its prominence in the pharmaceutical sector over its 50 years of operation. +

Over 1 Month

2.81%

Over 6 Months

-17.76%

Over 1 Year

6.50%

Over 3 Years

43.81%

Alkem Laboratories Ltd Summary

Close ₹4,953.30

Open ₹4,979

High ₹4,989.50

Low ₹4,881.10

Volume 45,830

Net Turnover (in Cr) ₹22.63

52Wk High ₹6,439.90

52Wk Low ₹4,407.05

52Wk High / Low

4,407.05

6,439.90

Alkem Laboratories Ltd Fundamentals

Key Financial Data

Market Cap (in Cr) ₹59,224.13

EPS (TTM) 187.04

Book Value (BV) 984.46

Div. Yield 0.81 %

P/E (TTM) 25.42

Price/Book Value 5.03

Delivery % 49.63 %

Face Value 2

Key Ratios

PE Ratio 33.80

PB Ratio 5.60

EV to Sales 6.05

PEG Ratio 0.63

ROA 14.68

ROE 17.56

Debt-Equity 0.11

Net Profit Margin 17.92

Operating Profit Margin 22.64

Alkem Laboratories Ltd Financials

Consolidated

Standalone

Yearly

Quarterly

Profit and Loss

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	12,978.42	11,815.34	10,796.84	9,098.22	8,448.58
Total Expenses	10,833.80	10,407.59	8,937.60	7,256.12	7,188.79
Profit Before Tax	2,023.13	1,304.77	1,844.28	1,842.10	1,259.79
Profit After Tax	1,811.46	1,006.81	1,680.32	1,617.77	1,149.31
Operating Profit After Depreciation	2,257.03	1,515.11	1,911.61	1,901.02	1,324.85

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	2,882.95	2,695.82	2,901.73	2,792.98	2,908.01
Total Non Current Assets	5,163.32	5,026.97	5,633.76	4,595.99	4,439.89
Total Current Assets	10,411.58	8,729.68	8,435.43	6,923.27	5,505.65
Total Assets	15,574.90	13,756.65	14,069.19	11,519.26	9,945.54
Total Shareholder's Fund	10,312.06	9,045.29	8,637.90	7,376.73	6,160.67

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash From Operating Activities	1,948.07	1,682.50	1,111.02	1,264.90	585.08
Net Cash Used In Investing Activities	-1,010.55	119.94	-1,432.63	-994.87	-737.34
Net Cash Used In Financing Activities	-1,145.01	-1,760.82	379.57	-271.75	79.15

Profit and Loss

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	10,053.71	9,320.84	9,029.70	7,409.69	6,773.06
Total Expenses	8,108.85	7,993.85	7,276.33	5,512.61	5,434.98
Profit Before Tax	1,881.03	1,326.99	1,753.37	1,884.30	1,338.08
Profit After Tax	1,747.15	1,134.47	1,541.25	1,685.08	1,264.42
Operating Profit After Depreciation	2,026.77	1,413.39	1,791.27	1,940.01	1,376.79

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	1,823.09	1,868.74	1,882.07	1,758.36	1,836.76
Total Non Current Assets	5,997.72	5,959.01	6,308.56	5,141.19	4,876.65
Total Current Assets	8,040.08	6,772.21	6,860.61	5,631.54	4,229.18
Total Assets	14,037.80	12,731.22	13,169.17	10,772.73	9,105.83
Total Shareholder's Fund	10,554.61	9,349.85	8,743.66	7,625.75	6,280.44

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash From Operating Activities	1,686.56	1,437.42	1,299.34	1,324.48	681.78
Net Cash Used In Investing Activities	-865.60	197.04	-1,669.33	-1,120.99	-995.17
Net Cash Used In Financing Activities	-959.04	-1,711.27	436.59	-208.96	172.64

Particulars (in ₹ Cr.)	2024-12	2024-09	2024-06	2024-03	2023-12
Total Revenue	3,374.28	3,414.67	3,031.82	2,935.82	3,323.87
Total Expenses	2,614.89	2,661.84	2,423.18	2,533.84	2,616.28
Profit Before Tax	731.07	780.26	619.36	367.34	654.90
Profit After Tax	640.79	701.96	550.24	304.48	604.28
Operating Profit after Depreciation	852.38	887.31	728.95	490.15	801.23

Particulars (in ₹ Cr.)	2024-12	2024-09	2024-06	2024-03	2023-12
Total Revenue	2,286.83	2,354.72	2,500.10	2,365.37	2,008.88
Total Expenses	1,629	1,714.43	1,879.47	1,957.85	1,516.54
Profit Before Tax	785.29	737.73	640.94	389.01	508.11
Profit After Tax	723.12	697.58	583.25	324.97	504.23
Operating Profit after Depreciation	873.90	816.21	726.73	491.31	636.91

Alkem Laboratories Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 4,919

S2 4,880.40

S3 4,847.20

Pivot 4,952.20

R1 4,990.80

R2 5,024

R3 5,062.60

Moving Average

20 SMA 4,898.12

50 SMA 4,831.83

100 SMA 5,118.91

200 SMA 5,436.21

Alkem Laboratories Ltd Corporate Actions

Dividend

Bonus

Splits

Rights

AGM

EGM

Alkem Laboratories Ltd

₹37.0/Share

Announcement Date 14 Feb 2025

Record Date 14 Feb 2025

Div Yield 1850%

AGM Date: 25 Aug 2022

48th Annual General Meeting of the Company shall be held on 25th August, 2022 and the cut-off date for the purpose of the said Annual General Meeting has been fixed as 18th August, 2022. Please find enclosed the outcome of the BM dated 13.5.22 The Board of Directors at its meeting held today i.e. 13th May, 2022, has, inter alia fixed 10th August, 2022 as the record date for the payment of final dividend and 18th August, 2022 as the Cut-off date for the purpose of the Annual General Meeting. The dividend, if declared by the shareholders, shall be paid on and from 30th August, 2022. Kindly take the same on record. Pursuant to Regulation 30 and 47 read alongwith Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the Regulation'), please find enclosed herewith a copy of advertisement published in today's Newspapers viz. Business Standard (English) and Mumbai Lakshadweep (Marathi) informing about completion of dispatch of Notice of the 48th AGM alongwith Annual Report for the financial year 2021-22 through electronic mode and availability of e-voting facility available to the shareholders. The same is also available on the website of the Company at www.alkemlabs.com. Kindly take the same on record. (As Per BSE Announcement dated on 12.07.2022) Pursuant to Regulation 30(2) read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that Mr. Balmiki Prasad Singh (DIN 00739856) has informed the Company on 17th August, 2022 about his unwillingness to offer himself for re-appointment at the Annual General Meeting of the Company scheduled to be held on 25th August, 2022 on grounds of his health and thereby intends to retire from the position of an Executive Director on the Board of Directors of the Company. Accordingly, Mr. Balmiki Prasad Singh shall retire upon conclusion of the ensuing Annual General Meeting. The requisite disclosure as required under regulation 30 read with Schedule III, Para A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular No. CIR/CFD/CMD/4/2015 dated 30th September, 2015 is attached as ''Annexure I''. Kindly take the same on your records. (As Per BSE Announcement Dated on 18.08.2022) This is with reference to the 48th Annual General Meeting (''AGM'') of the Company held on Thursday, 25th August, 2022 at 11.00 a.m. through Video Conferencing (VC)/ Other Audio Visual Means (OAVM). Please find enclosed herewith the details regarding the brief proceedings of the 48th Annual General Meeting (AGM) of the Company and the details regarding the voting results of the business transacted at the said AGM in the prescribed format. Further, we are also enclosing the Report of the Scrutinizer on remote e-voting and e-voting during the AGM. You are requested to take a note of the same. This is with reference to the 48th Annual General Meeting (''AGM'') of the Company held on Thursday, 25th August, 2022 at 11.00 a.m. through Video Conferencing (VC)/ Other Audio Visual Means (OAVM). Please find enclosed herewith the details regarding the brief proceedings of the 48th Annual General Meeting (AGM) of the Company and the details regarding the voting results of the business transacted at the said AGM in the prescribed format. Further, we are also enclosing the Report of the Scrutinizer on remote e-voting and e-voting during the AGM. You are requested to take a note of the same. (As Per BSE Announcement Dated on 25.08.2022) Alkem Laboratories Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. (As Per BSE Announcement Dated on 26.08.2022)

AGM Date: 25 Aug 2023

The Board of Directors at its meeting held today i.e. 19th May, 2023, has, inter alia: 1. recommended a final dividend of Rs. 10/- (Rupees Ten only) per equity share of Rs. 2/- each for the financial year ended 31st March, 2023, for the approval of the shareholders of the Company at the ensuing Annual General Meeting. 2. fixed that the 49th Annual General Meeting of the Company shall be held on 25th August, 2023 and the cut-off date for the purpose of the said Annual General Meeting has been fixed as 18th August, 2023. 3. fixed 10th August, 2023 as the record date for the purpose of payment of final dividend. The dividend, if declared by the shareholders, shall be paid on and from 30th August, 2023. The meeting of the Board of Directors of the Company commenced at 11.00 a.m. and concluded at 1.30 p.m. Kindly take the same on record. Pursuant to Regulation 30 and 47 read alongwith Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of advertisement published in today''s Newspapers viz. Business Standard (English) and Mumbai Lakshadeep (Marathi) for information regarding 49th Annual General Meeting of the Company to be held through video conferencing (VC)/ other audio visual means (OAVM). The same is also available on the website of the Company at www.alkemlabs.com. Kindly take the same on record. Pursuant to Regulation 30 and 47 read alongwith Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of advertisement published in today''s Newspapers viz. Business Standard (English) and Mumbai Lakshadeep (Marathi) for information regarding 49th Annual General Meeting of the Company to be held through video conferencing (VC)/ other audio visual means (OAVM). The same is also available on the website of the Company at www.alkemlabs.com. Kindly take the same on record. (As Per BSE Announcement Dated on 05.07.2023) Please find enclosed herewith the Notice of the 49th Annual General Meeting of the Company scheduled to be held on Friday, 25th August, 2023 at 11.00 a.m. through Video Conferencing (VC)/ Other Audio Visual Means (OAVM) alongwith the Annual Report for financial year 2022-2023. The same is also available on the website of the Company at www.alkemlabs.com Kindly take the same on record. (As Per BSE Announcement dated on 14.07.2023) Pursuant to Regulation 30 and 47 read alongwith Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of advertisement published in today''s Newspaper viz. Business Standard (English) and Mumbai Lakshadweep (Marathi) informing about completion of dispatch of Notice of the 49th AGM (including details of e-voting facility) alongwith Annual Report for financial year 2022-23 through electronic mode. The same is also available on the website of the Company at www.alkemlabs.com. Kindly take the same on record. (As Per BSE Announcement Dated on 15.07.2023) Please find enclosed herewith the details regarding the brief proceedings of 49th Annual General Meeting (AGM) of the Company held on 25th August, 2023 at 11:00 AM through Video Conferencing (VC)/ Other Audio Visual Means (OAVM) and the details regarding the voting results of the business transacted at the said AGM in the prescribed format. Further, we are also enclosing the Report of the Scrutinizer on remote e-voting and e-voting during the AGM. Kindly take the same on record. Please find enclosed herewith the details regarding the brief proceedings of Annual General Meeting (AGM) of the Company held on 25th August, 2023 at 11:00 AM through Video Conferencing (VC)/ Other Audio Visual Means (OAVM) and the details regarding the voting results of the business transacted at the said AGM in the prescribed format. Further, we are enclosing the Report of the Scrutinizer on remote e-voting and e-voting during the AGM. Kindly take the same on record. (As per BSE Announcement Dated on 25/08/2023) With reference to the captioned subject, please find attached herewith the updated proceedings of 49th Annual General Meeting (AGM) of the Company for including the conclusion time of the AGM. (As Per BSE Announcement Dated on 08/04/2024)

AGM Date: 30 Aug 2024

Please find enclosed herewith the outcome of the Board meeting dated 29th May, 2024 The BOD at its meeting held today has fixred 10.8.24 as the record date for payment of final dividend and 23.08.24 as cut off date for purpose of AGM (As Per BSE Announcement Dated on 29.05.2024) Please find enclosed herewith the details regarding the brief proceedings of 50th Annual General Meeting (AGM) of the Company held on 30th August, 2024 at 11.00 a.m. through Video Conferencing (VC) / Other Audio Visual Means (OAVM) and the details regarding the voting results of the business transacted at the said AGM in the prescribed format. Further we are also enclosing the Report of the Scrutinizer on remote e-voting and e-voting during the AGM. Kindly take the same on record. (As per BSE Announcement Dated on 30/08/2024)

Alkem Laboratories Ltd Peer Comparison

Company	Price	Market Cap (in Cr)
Sun Pharmaceutical Industries Ltd	₹1,751.05	₹4,20,135.55
Divis Laboratories Ltd	₹5,638.35	₹1,49,680.48
Cipla Ltd	₹1,515.45	₹1,22,390.34
Torrent Pharmaceuticals Ltd	₹3,254.85	₹1,10,153.97
Mankind Pharma Ltd	₹2,582.65	₹1,06,554.59

Alkem Laboratories Ltd Top Mutal Funds Invested

Fund Name	AUM
SBI Large & Midcap Fund	2.45%
ICICI Pru Multi-Asset Fund	0.97%
ICICI Pru Large & Mid Cap Fund	2.62%
SBI Contra Fund	1.16%
AXIS Midcap Fund	1.55%

Alkem Laboratories Ltd News

Alkem Labs' subsidiary concludes acquisition of 100% stake in Bombay Ortho

Alkem Laboratories said that its wholly owned subsidiary Alkem Medtech has completed the acquisition of 100% stake of Bombay Ortho Industries.

17 Apr 2025, 02:49 pm

Alkem MedTech acquires Bombay Ortho Industries

17 Apr 2025, 09:43 am

Alkem Lab gains as Bioequivalence Center clears USFDA inspection without observations

Alkem Laboratories added 1.93% to Rs 4,795 after the company announced that the United States Food and Drug Administration (USFDA) conducted a Bioresearch Monitoring (BIMO) inspection at its Bioequivalence Center in Taloja, Maharashtra.

17 Mar 2025, 09:57 am

Alkem Lab's Bioequivalence Center clears USFDA inspection without observations

Alkem Laboratories announced that the United States Food and Drug Administration (USFDA) conducted a Bioresearch Monitoring (BIMO) inspection at its Bioequivalence Center in Taloja, Maharashtra, from 10 March to 13 March 2025.

15 Mar 2025, 12:44 pm

Alkem Laboratories launches generic Empagliflozin in India

Alkem Laboratories said that it has launched generic Empagliflozin and its combinations in India under the brand name Empanorm.

12 Mar 2025, 10:34 am

Alkem Laboratories Ltd Stock Analysis

Annual revenue for Alkem Laboratories Ltd increased by 7.86% to ₹10,053.71 crore in FY 2024 from ₹9,320.84 crore in FY 2023.
Annual Net Profit for Alkem Laboratories Ltd increased by 54.01% to ₹1,747.15 crore in FY 2024 from ₹1,134.47 crore in FY 2023.
Promoter Shareholding in Alkem Laboratories Ltd remains unchanged by 0.00% in the most recent quarter, from 55.66% in September 2024 to 55.66% in December 2024.
Alkem Laboratories Ltd delivered a 1-year return of 6.50% compared to the Nifty 50, which provided a return of 8.44% as of the last trading session.
Alkem Laboratories Ltd share price moved down by 0.09% from its previous close of INR ₹4,957.60. The latest Alkem Laboratories Ltd share price is INR ₹4,953.30.
Alkem Laboratories Ltd share price today has been at a low of 4,881.10 and a high of 4,989.50. Over the past 52 weeks, the Alkem Laboratories Ltd share price has seen a low of 4,407.05 and a high of 6,439.90.

About Alkem Laboratories Ltd

Alkem Laboratories Ltd is a pioneering pharmaceutical company. It has been a key player in the industry for many years since its start in 1973. Headquartered in Mumbai, Maharashtra, the company specialises in developing, manufacturing, and marketing a wide range of pharmaceutical formulations. It also does the same for generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals.
Founded by Samprada Singh, Alkem Laboratories is currently managed by Sandeep Singh. He is the Managing Director & Executive Director. The company’s extensive product portfolio covers therapeutic areas such as anti-infective and pain and analgesics. It also provides products of vitamins/minerals/nutrients. Their list also includes products for cardiac, diabetology, gynaecology, and neuro/central nervous system. There are also products for dermatology, anti-osteoporosis, anti-diabetes, muscle relaxants, and cardiovascular.
Alkem Laboratories has secured its position as one of India’s largest pharmaceutical companies. It holds the top spot in the Indian trade generics market. This achievement highlights the company’s commitment to quality and innovation in the pharmaceutical sector.
The promoter shareholding of the company is at 55.66%. The registered office of Alkem Laboratories is located at Reality Ware Housing (P) LTD, GAT NO 2323/1, Pune, Maharashtra 412207. The company’s management team, led by experienced professionals, continues to drive its growth and success in the industry.
Here are the main managing promoters of the company:

Basudeo N Singh
Sandeep Singh
Madhurima Singh
Srinivas Singh
Mritunjay Kumar Singh

Alkem Laboratories Ltd’s dedication to delivering high-quality pharmaceutical products has solidified its reputation as a leader in the sector. It has a strong focus on research and development. The company aims to provide effective and affordable healthcare solutions to patients worldwide.

Company History

Alkem Laboratories Ltd was founded in 1973 by Samprada Singh. It has grown to become one of India’s leading pharmaceutical companies. The company started its journey with a vision to provide affordable and high-quality healthcare solutions to people across the country. Headquartered in Mumbai, Maharashtra, Alkem Laboratories has made significant strides in the pharmaceutical sector over the past decades.
The company’s first manufacturing unit was established in Taloja near Mumbai in 1978. This marked the beginning of Alkem’s journey in the manufacturing of pharmaceutical formulations and generic drugs. In 1992, Alkem expanded its production capabilities by setting up a second manufacturing plant in Mandva, Gujarat. This later became an API (Active Pharmaceutical Ingredients) facility in 2005.
Alkem Laboratories has built a strong reputation for its commitment to quality and innovation. The company’s extensive product portfolio includes branded generics, generic drugs, and APIs. It also provides nutraceuticals in therapeutic areas such as anti-infective, pain, and analgesics. They also provide products concerning vitamins/minerals/nutrients, cardiac, diabetology, and gynecology. It also covers sections like neuro/central nervous system, anti-diabetes, dermatology, anti-osteoporosis, muscle relaxants, and cardiovascular.
Under the leadership of Sandeep Singh who is the Managing Director & Executive Director, Alkem Laboratories has continued to grow and expand its market presence. The company is dedicated to research and development. This has enabled it to stay ahead of industry trends and provide effective healthcare solutions to its customers.
Alkem Laboratories is recognized as one of the largest pharmaceutical companies in India. It holds the top position in the Indian trade generics market. This achievement highlights the company’s commitment to quality and innovation in the pharmaceutical sector. The registered office of Alkem Laboratories is located at Reality Ware Housing (P) LTD, GAT NO 2323/1, Pune, Maharashtra 412207.
Alkem Laboratories Ltd was incorporated as a private limited company on August 8, 1973, in Patna, Bihar, under the Companies Act, 1956. The company was initially named "Alkem Laboratories Private Limited" and later became a deemed public limited company on October 26, 1988.
The founder, Samprada Singh, had humble beginnings in a middle-class family in Okri village, Jehanabad district, Bihar. Despite financial challenges, Singh aspired to provide healthcare solutions to people. He started his journey by opening a medical store in 1953. It later ventured into pharmaceutical distribution with the establishment of Laxmi Pharma. His vision and determination led to the foundation of Alkem Laboratories. It aimed to make a difference in the healthcare sector.
In 1978, Alkem Laboratories set up its first manufacturing unit in Taloja, near Mumbai, marking a significant milestone in its journey. The company continued to expand its production capabilities. In 1992, it established a second manufacturing plant in Mandva, Gujarat. This facility later became an API (Active Pharmaceutical Ingredients) production unit in 2005. It further strengthens Alkem’s position in the pharmaceutical industry.
Alkem Laboratories has consistently focused on innovation and quality. It is ensuring that its products meet the highest standards. The company is committed to research and development. This has enabled it to introduce a wide range of pharmaceutical formulations, generic drugs, APIs, and nutraceuticals.
Under the leadership of the Managing Director & Executive Director Sandeep Singh, Alkem Laboratories has continued to grow and expand its market presence. The company is dedicated to providing affordable and high-quality healthcare solutions. It has earned it a strong reputation in the industry.
Alkem Laboratories Ltd has made significant contributions to the pharmaceutical industry. They did this through its innovative solutions and dedication to providing affordable healthcare. With a strong focus on research and development, the company continues to lead the way in delivering high-quality pharmaceutical products to its customers.

FAQ’s

What is the share price of Alkem Laboratories Ltd today?

Alkem Laboratories Ltd share price as on 18 Apr 2025 is ₹ 4953.3

What is the Market Cap of Alkem Laboratories Ltd?

The market cap of Alkem Laboratories Ltd stock is ₹59,224.13 Cr.

What is the PE Ratio of Alkem Laboratories Ltd?

The Price to Earnings (P/E) Ratio of Alkem Laboratories Ltd is 33.80

What is the PB Ratio of Alkem Laboratories Ltd?

The Price to Book (P/B) Ratio of Alkem Laboratories Ltd is 5.60

What is the 52 week high of Alkem Laboratories Ltd Share Price?

The 52 week high of Alkem Laboratories Ltd share price stands at ₹6,439.90

What is the 52 week low of Alkem Laboratories Ltd Share Price?

The 52 week low of Alkem Laboratories Ltd share price stands at ₹4,407.05

How can I buy shares of Alkem Laboratories Ltd?

Simply open a demat account with Torus Digital and place an order to buy shares of Alkem Laboratories Ltd.

Alkem Laboratories Ltd Share Price

About Alkem Laboratories Ltd

Alkem Laboratories Ltd Summary